Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years

After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

California governor vetoes bill to cap insulin prices at $35 per month

California Gov. Gavin Newsom vetoed a bill that would have capped insulin prices at $35 per month, citing his existing plan to make California’s own

October 10, 2023

Heidelberg Pharma Announces Changes to the Executive Management Board – Biotech Investments

Heidelberg Pharma AG / Key word(s): Personnel Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board 29-Nov-2023 / 11:56 CET/CEST Disclosure of

November 30, 2023

GSK to put £50M into Cambridge University partnership; Angelini’s new deal

Plus, news about Takeda, Foresee Pharmaceuticals and Capricor Therapeutics: GSK, Cambridge University team up on immune diseases: The UK drugmaker is pouring £50 million …

October 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.